Understanding Your Diagnosis: HTNB / Bilginturan Syndrome

Receiving a diagnosis of Brachydactyly-Arterial Hypertension Syndrome—also known as HTNB or Bilginturan Syndrome—can feel like entering uncharted territory. This is an ultra-rare genetic condition that connects two seemingly unrelated features: unusually short fingers and toes (brachydactyly) and severe high blood pressure (hypertension) ^[1][2].

Because this condition is so rare, there is no official number for how many people have it worldwide ^[1]. Most of what doctors know comes from studying a small number of families across several generations ^[3]. While the “rare” label can be overwhelming, understanding the mechanics of the syndrome is the first step toward managing it effectively.

What This Diagnosis Does and Does Not Mean: A confirmed pathogenic PDE3A result establishes the genetic diagnosis. However, it does not by itself predict your exact severity, your individual medication response, or your personal stroke risk.

Understanding the “Two-Part” Diagnosis

The syndrome is defined by a specific combination of physical and internal traits.

• Skeletal Features (Brachydactyly Type E): This refers to the shortening of certain bones in the hands and feet (metacarpals and metatarsals) ^[4]. It is often accompanied by short stature, meaning you may be shorter than other members of your family who do not have the condition ^[1].
• Severe Hypertension: The high blood pressure in HTNB is unique because its primary mechanism is vascular rather than ordinary renal sodium retention ^[5]. While this genetic mechanism is primary, patients can still have ordinary lifestyle contributors to blood pressure and should follow individualized advice ^[6].

The condition is autosomal dominant, meaning if one parent has the gene variant, there is a 50% chance of passing it to each child ^[1][4]. However, in some cases, it can appear for the first time in an individual due to a new (de novo) genetic change ^[3].

The Role of the PDE3A Gene

The root cause of HTNB is a mutation in the PDE3A gene ^[1]. This gene provides instructions for making an enzyme that helps regulate how blood vessel walls relax and contract ^[7]. In HTNB, this enzyme becomes overactive (gain-of-function), leading to increased resistance in your peripheral blood vessels ^[1][6]. This extra resistance forces the heart to pump against higher pressure, which leads to the characteristic severe hypertension ^[6].

The same gene is also involved in bone development. When it is overactive, it alters the signaling pathways that tell bones how long to grow, which results in the shortened fingers and toes seen at birth or in early childhood ^[6][8].

Glossary of Key Terms:

• PDE3A: The gene containing the mutation responsible for HTNB.
• Gain-of-function: A mutation that makes a gene or enzyme overactive.
• cAMP: A molecule that tells blood vessels to relax; broken down too quickly in HTNB.
• PTHrP: A protein involved in bone growth; its signaling is altered in this condition.
• VUS: Variant of Uncertain Significance, meaning a genetic change was found but it is unclear if it causes disease.
• Cascade testing: Identifying a genetic variant in one person (the proband) and then testing their at-risk biological relatives.

Navigating an Ultra-Rare Diagnosis

One of the most challenging aspects of HTNB is its rarity. Because the incidence rate is unknown, you may find that many doctors—even specialists—have never treated a patient with this specific syndrome before ^[1][4].

This does not mean your condition is untreatable. It does mean that your care will likely require a multidisciplinary approach, involving specialists like:

• Cardiologists to manage blood pressure.
• Geneticists to confirm the specific variant and provide family counseling.
• Nephrologists (kidney specialists) to monitor overall vascular health, even though the kidneys themselves are typically not the primary cause of the high blood pressure in this syndrome ^[2][9].

Managing the Emotional Impact

It is entirely normal to feel a range of emotions—from shock and fear to frustration—when diagnosed with a syndrome that has a name you’ve never heard before. Research shows that patients and families facing ultra-rare diagnoses often feel a sense of “finding their way in the dark” ^[10].

While the hypertension in HTNB is severe and requires lifelong attention, the evidence is clear: it is medically responsive ^[3][4]. When identified early and treated with standard antihypertensive medications, blood-pressure control is expected to reduce vascular risk, based on general hypertension care and reported experience, even if condition-specific outcome data are limited ^[4][5]. Getting a diagnosis is the pivotal moment that allows you to shift from an unexplained risk to a managed health plan.

Moving Toward Stability

The hypertension in HTNB is age-dependent, often becoming more severe as a person moves from childhood into adulthood ^[1][11]. Because of this, early and consistent blood pressure monitoring is essential ^[4]. Modern treatment frameworks, which may include combinations of ACE inhibitors, calcium-channel blockers, or diuretics, are used in general hypertension care to help patients reach safe blood pressure levels ^[12][3].

Your diagnosis is a tool. It gives your medical team a specific target (the PDE3A pathway) and a clear goal: maintaining a stable blood pressure to protect your long-term vascular health ^[4][13].